About Cellulac
Cellulac is a company based in London (United Kingdom) founded in 2009 was acquired by Integumen in April 2018. The company has 2 employees as of December 31, 2021. Cellulac operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter London, United Kingdom
- Employees 2 as on 31 Dec, 2021
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Cellulac Plc
- Date of Incorporation 26 Jul, 2013
- Jurisdiction LONDON, ENGLAND
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Cellulac
Unlock access to complete
Unlock access to complete
Funding Insights of Cellulac
Detailed funding history for Cellulac
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Cellulac
Cellulac has secured backing from 1 investor. Prominent investors backing the company include Integumen.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Develops innovative technologies for skincare and wound dressing products.
|
Locked | Locked | Locked |
Investor details for Cellulac
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cellulac
Investment portfolio details for Cellulac
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Cellulac
Detailed financials for Cellulac
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cellulac Comparisons
Peer comparison for Cellulac
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Cellulac
Cellulac operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Yeast cells are genetically engineered to produce medicinal products.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
CRISPR-engineered cell and gene therapies are developed for research applications.
|
Detailed competitors of Cellulac
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cellulac
Complete news archive for Cellulac
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cellulac
Cellulac was founded in 2009.
Cellulac is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
As of Dec 31, 2021, the latest employee count at Cellulac is 2.
Cellulac is an industrial biotechnology company that acquires or licenses bioprocess technologies for the production of valuable products such as biofuels, solvents and omega-3 dietary supplements. The company specializes in recovering significant value from undervalued assets by integrating biological and engineering efficiencies to create bioprocesses with reduced costs and improved margins, for the production of biofuels and biochemicals. The technology platforms and processes currently being commercialized by the company include Bioplastics Solutions (a vertically integrated waste management solution for hospitals using biodegradable hospital consumables, in a closed, carbon-neutral loop from production to disposal), Cellulac Cellulosic ethanol plant (for the production of ethanol, in addition to other valuable products such as ethyl lactate, sodium bicarbonate, lactic acid, biogas, plant proteins etc.), algae wet recovery technology (for efficient recovery of algal lipids), etc. Most of Cellulacs bioprocesses are enabled by their proprietary SoniqueFlo technology that uses a supersonic controllable shockwave formed from the forced flow of steam or gas into a specially shaped chamber. The unique design features and capabilities of the SoniqueFlo system allow the use of 2nd and 3rd generation feedstocks for the energy-efficient production of commercial quantities of C5 and C6 sugars. The company is also part of collaborations and consortia for development of various products and technologies, such as SPLASH and FUEL4ME - EU projects for developing biobased production platforms using algae, AlgaePARC (an industry consortium for development of algal biodiesel), ALGZYM (an EU project for commercialization of a green enzyme technology for omega-3 oil production from algae).
Cellulac's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Cellulac has 1 investor. Key investors include Integumen.